Similar to de novo AML, post‐MDS AML cells treated with MLN4924 exhibited decreased Neddylation of CRLs (Fig. 3B, top panel), increased levels of c‐Myc (Fig. 3B, second panel), and upregulation of Noxa at the mRNA and protein levels (Fig. 3B, 3C). The gene discussed is MYC; the disease is myelodysplastic syndrome.